annb0t
Top 20
Bionomics Ltd
BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary Endpoint Subjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to Placebo BNC210 Demonstrated Favourable Safety and Tolerability Profile Consistent with Prior Experience Company is Continuing Analysis of the Data and Evaluating Next Steps with Cash Runway into mid-2024
ADELAIDE, Australia, Dec. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq:...
>>> Read more: Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder
BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary Endpoint Subjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to Placebo BNC210 Demonstrated Favourable Safety and Tolerability Profile Consistent with Prior Experience Company is Continuing Analysis of the Data and Evaluating Next Steps with Cash Runway into mid-2024
ADELAIDE, Australia, Dec. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq:...
>>> Read more: Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder
